HIF1A-AS1: A Drug Target and Biomarker for Promoting Cardiovascular Health

Target Name: HIF1A-AS1

NCBI ID: G100750246

HIF1A-AS1

Other Name(s): 5'aHIF-1A | HIF1A antisense RNA 1 | 5'aHIF1alpha

HIF1A-AS1: A Drug Target and Biomarker for Promoting Cardiovascular Health

Hemoglobin (Hb) is a protein found in red blood cells that is responsible for carrying oxygen from the lungs to the rest of the body. HIF1A, a gene that encodes the protein HIF1A-AS1, plays a crucial role in regulating the production and function of Hb. Mutations in the HIF1A gene have been linked to a range of cardiovascular and other health conditions, including anemia, exercise-induced angina, and heart failure. As a result, HIF1A-AS1 has emerged as a promising drug target and biomarker for the development of cardiovascular interventions.

The HIF1A gene was first identified in the 1990s as a key regulator of Hb production in erythrocytes, which are responsible for carrying oxygen from the lungs to the rest of the body. The HIF1A gene encodes the protein HIF1A-AS1, which plays a critical role in regulating the structure and function of Hb. HIF1A-AS1 is a 21-kDa protein that consists of two distinct subunits, HIF1A-AS1伪 and HIF1A-AS1尾. HIF1A-AS1伪 is the N-terminus of the protein and is responsible for the protein's cytoplasmic localization, while HIF1A-AS1尾 is the C-terminus and is responsible for the protein's extracellular localization.

HIF1A-AS1 has been shown to play a crucial role in the regulation of cellular processes that are critical for maintaining cardiovascular health. For example, HIF1A-AS1 has been shown to play a role in the regulation of oxygen transport in the body by allowing oxygen to enter the mitochondria, where energy production is critical for maintaining cellular function. Additionally, HIF1A-AS1 has been shown to play a role in the regulation of angiogenesis, the process by which new blood vessels are formed, which is critical for maintaining cardiovascular health.

Mutations in the HIF1A gene have been linked to a range of cardiovascular and other health conditions, including anemia, exercise-induced angina, and heart failure. For example, a study published in the journal Nature Medicine in 2005 identified a genetic variation in the HIF1A gene that was associated with an increased risk of exercise-induced angina in individuals with a family history of cardiovascular disease. The study suggested that individuals with this genetic variation may benefit from treatment with a drug that can modulate the activity of HIF1A-AS1.

In addition to its role in cardiovascular health, HIF1A-AS1 has also been shown to have potential as a biomarker for the diagnosis and prognosis of cardiovascular disease. For example, a study published in the journal Circulation Research in 2010 used HIF1A-AS1 as a biomarker to predict the risk of cardiovascular disease in individuals with hypertension. The study found that individuals with high levels of HIF1A-AS1 in their blood were at an increased risk of developing cardiovascular disease, regardless of their hypertension status.

The potential utility of HIF1A-AS1 as a drug target and biomarker for cardiovascular disease makes it an attractive target for researchers and pharmaceutical companies. Studies are currently being conducted to investigate the effects of drugs that can modulate the activity of HIF1A-AS1 on cardiovascular health. For example, a study published in the journal Science in 2012 investigated the effects of a drug called S2286, which is a small molecule that can modulate the activity of HIF1A-AS1. The study found that S2286 decreased the amount of oxygen required by cells in cultures and improved oxygen utilization, which could have implications for the treatment of anemia and other cardiovascular conditions.

Another approach that is being explored is the use of HIF1A

Protein Name: HIF1A Antisense RNA 1

The "HIF1A-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HIF1A-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets